がん治療薬市場：がんタイプ、療法、エンドユーザー、地域別、2024年～2031年

がん治療薬市場の評価、2024年～2031年

がん治療薬市場は大きな節目を迎え、2023年には1,499億2,000万米ドルに達しました。研究開発の活発化、製薬企業間の協力関係の強化、ヘルスケア部門における投資の拡大など、さまざまな要因がこの達成に拍車をかけた。同市場は、2024年から2031年までの予測期間中に14.6%のCAGRが予測され、有望な軌道に乗ると予測されています。2031年までには4,914億1,000万米ドルという驚異的な規模に急騰すると予想され、これは業界内の持続的な勢いと進化するダイナミクスを反映しています。

この成長を支えているのは、世界のがん罹患率の上昇、早期発見を促進する政府の取り組み、がん研究の着実な増加、技術の進歩といった要因であり、これらすべてががん治療薬の進歩に寄与しています。

がん治療薬市場定義/概要

がん治療薬には、放射線療法、化学療法、外科手術など、腫瘍の成長を阻害するためにがん細胞の変化を標的とする治療法が含まれます。これらの治療法の適用は、がんの種類やステージによって異なり、免疫療法、標的療法、ホルモン療法、幹細胞移植などの治療法を模索する調査や臨床試験が進行中です。市場セグメンテーションは、がんの種類とエンドユーザーに基づいて行われ、特にアジア、欧州、南北アメリカにおいて、2031年までに倍増すると予想される世界のがん罹患率の上昇が市場を牽引しています。

市場の成長は、製薬企業間の協力や研究努力の増加によってさらに促進されます。市場拡大の原動力となっているのは、がん啓発に対する政府の取り組みと個別化医療の需要です。

がん治療薬市場の成長を促す要因は何か？

効果的な治療オプションに対する需要は、特にアジア、欧州、南北アメリカなどの地域における世界のがんの有病率の上昇によって促進されています。このようながん患者の増加により、先進的な治療薬が必要とされ、市場の拡大につながっています。がん治療薬の革新は、腫瘍学分野における研究開発の活発化によって大きく寄与しています。研究や臨床試験を通じた絶え間ない探求は、新薬や治療法の発見を促し、それによって市場はより効果的な解決策で潤う。

さらに、イノベーションとがん治療薬開発の加速は、製薬会社、研究機関、さまざまな利害関係者の協力によって促進されます。このようなパートナーシップは、リソースのプールと知識の共有を促進し、より強固なパイプラインと新薬の迅速な市場導入をもたらします。さらに、がんに対する認識を高め、早期発見を促進し、研究資金を提供することを目的とした政府の取り組みも、市場の成長を後押ししています。

がん患者が利用できる治療選択肢の拡大は、ゲノム検査の進歩や技術革新に後押しされ、個々の患者のプロファイルに合わせた個別化医療への需要が高まっていることが背景にあります。このような要因の融合が、がん治療薬市場の継続的な進展と拡大に有利な環境を生み出しています。

がん治療薬市場の売上を急落させている要因とは？

ブロックバスター医薬品の特許切れによるジェネリック医薬品の登場は、競争を激化させ、ブランドがん治療薬の価格を引き下げます。この競争の激化は製薬企業に課題をもたらし、企業収益の減少につながります。また、新しいがん治療薬へのアクセスは、医薬品の承認や償還に関する厳しい規制要件やヘルスケア支払者からの価格圧力によって制限されています。規制当局の承認の遅れや償還政策の変更は、がん治療薬の採用をさらに制限し、売上高にマイナスの影響をもたらします。

特に特許保護が切れた薬剤については、ブランドがん治療薬のジェネリック医薬品のイントロダクションが、オリジネーター企業にとって大幅な価格低下と売上減少の一因となっています。治療パラダイムは、がん研究の進歩や、免疫療法や分子標的治療などの新しい治療法に対する医療提供者の嗜好の変化によっても影響を受ける。このシフトは従来の化学療法の利用を減少させ、従来のがん治療薬の売上にさらに影響を与える可能性があります。景気後退、医療費支出の変化、償還の変動などの経済要因や、治療のアドヒアランスやアクセスに関する課題は、この競合情勢の中で製薬企業が収益成長を維持する上で直面する課題をさらに複雑にしています。

目次

第1章 世界のがん治療薬市場、イントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• バリデーション
• 一次インタビュー
• データソース一覧

第4章 世界のがん治療薬市場の展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 がん治療薬の世界市場、がんタイプ別

• 概要
• 血液がん
• 肺がん
• 乳がん
• 消化器がん
• 大腸がん
• 婦人科がん
• 前立腺がん
• その他

第6章 がん治療薬の世界市場、療法別

• 概要
• 化学療法
• 標的療法
• 免疫療法
• ホルモン療法
• その他

第7章 がん治療薬の世界市場、エンドユーザー別

• 概要
• 病院
• 専門クリニック
• がん・放射線治療センター

第8章 がん治療薬の世界市場、地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第9章 がん治療薬の世界市場、競合情勢

• 概要
• 各社の市場ランキング
• 主な開発戦略

第10章 企業プロファイル

• F. Hoffmann-La Roche AG
• Bristol-Myers Squibb Company
• AbbVie, Inc.
• Johnson & Johnson
• Celgene Corporation
• Astellas Pharma Inc.
• Pfizer, Inc.
• Novartis AG
• Merck KGaA
• Bayer AG

第11章 付録

• 関連調査

Cancer Therapeutics Market Valuation - 2024-2031

Significant milestones were achieved in the Cancer Therapeutics Market, with a value of USD 149.92 Billion attained in 2023. Various factors, including heightened research and development endeavors, greater collaboration among pharmaceutical entities, and amplified investments within the healthcare sector, fueled this achievement. The market is anticipated to witness a promising trajectory, with a projected CAGR of 14.6% during the forecast period from 2024 to 2031. By 2031, it is expected to soar to an impressive value of USD 491.41 Billion, reflecting the sustained momentum and evolving dynamics within the industry.

This growth is underpinned by factors such as the escalating prevalence of cancer globally, governmental initiatives promoting early detection, and the steady rise in cancer research endeavors, coupled with technological advancements, all contributing to the advancement of cancer therapeutics.

Cancer Therapeutics Market: Definition/Overview

Cancer therapeutics encompass treatments aimed at targeting alterations in cancer cells to impede tumor growth, including radiotherapy, chemotherapy, and surgery. The application of these therapies varies based on cancer type and stage, with ongoing research and clinical trials exploring treatments such as immunotherapy, targeted therapy, hormone therapy, and stem cell transplant. Market segmentation, based on cancer type and end users, is driven by the global rise in cancer prevalence, expected to double by 2031, particularly in Asia, Europe, and the Americas.

Market growth is further propelled by collaboration between pharmaceutical companies and increased research efforts. Market expansion is driven by government initiatives for cancer awareness and the demand for personalized medicine.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

What Factors are Driving the Growth of the Cancer Therapeutics Market?

The demand for effective treatment options is propelled by the escalating prevalence of cancer globally, particularly in regions such as Asia, Europe, and the Americas. This rise in cancer cases necessitates advanced therapeutics, leading to market expansion. Innovation in cancer therapeutics is significantly contributed by heightened research and development endeavors within the field of oncology. Continuous exploration through studies and clinical trials facilitates the discovery of novel drugs and treatment modalities, thereby enriching the market with more effective solutions.

Moreover, innovation and the acceleration of cancer therapeutics development are fostered by collaborative efforts among pharmaceutical companies, research institutions, and various stakeholders. These partnerships facilitate resource pooling and knowledge sharing, resulting in more robust pipelines and the quicker introduction of new drugs to the market. Furthermore, market growth is bolstered by government initiatives aimed at raising cancer awareness, promoting early detection, and providing funding for research.

The expansion of treatment options available to cancer patients is driven by the growing demand for personalized medicine tailored to individual patient profiles, fueled by advances in genomic testing and technological innovations. This convergence of factors creates a favorable environment for the continuous progression and expansion of the Cancer Therapeutics Market.

What Factors are Plummeting Sales of Cancer Therapeutics Market?

The availability of generic versions due to patent expirations on blockbuster drugs intensifies competition and drives down prices for branded cancer therapeutics. This increased competition poses challenges for pharmaceutical companies, leading to reduced sales revenue. Also, easy accessibility to new cancer therapeutics is restricted by stringent regulatory requirements for drug approval and reimbursement, as well as pricing pressures from healthcare payers. Delays in regulatory approvals or changes in reimbursement policies further limit the adoption of cancer therapeutics, resulting in negative impact on sales.

The introduction of generic versions of branded cancer therapeutics, particularly for drugs losing patent protection, contributes to significant price erosion and decreased sales for originator companies. Treatment paradigms are also influenced by advances in cancer research, and shifting preferences of healthcare providers towards emerging therapies such as immunotherapy and targeted treatments. This shift may reduce the utilization of traditional chemotherapy, further impacting sales of conventional cancer therapeutics. Economic factors, including downturns, changes in healthcare spending, and fluctuations in reimbursement, as well as challenges related to treatment adherence and access issues, further compound the challenges faced by pharmaceutical companies in maintaining revenue growth in this competitive landscape.

Category-Wise Acumens

Which Therapy Type Category Holds the Dominant Market Share in the Cancer Therapeutics Market?

In the forecasted period, the targeted therapy segment is expected to demonstrate the highest Compound Annual Growth Rate (CAGR), attributed to its specificity toward cancer cells while minimizing toxicity to off-target cells. This category encompasses various therapeutic approaches, such as hormone therapies, gene expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies, signal transduction inhibitors, and toxin delivery molecules.

With cancer cells precisely targeted and healthy cells spared from harm, targeted therapy presents a promising avenue for more effective and tolerable cancer treatment options. Consequently, it contributes significantly to its dominance in the Cancer Therapeutics Market.

Will the Emergence of Cancer and Radiation Therapy Centres Drive Growth in the Cancer Therapeutics Market?

The growth of the Cancer Therapeutics Market is expected to be driven by the emergence of Cancer and Radiation Therapy Centres. It is anticipated that the largest market share will be held by the Cancer & Radiation Therapy Centre due to several factors. These centers are regarded as pivotal in the administration of cancer therapeutics, serving as hubs for a significant number of cancer treatments. Patients are often provided with a variety of treatments, including chemotherapy, radiotherapy, and targeted therapy, all of which contribute to the demand for cancer therapeutics.

Additionally, specialized equipment and expertise required for advanced treatment modalities are often housed within these centers, further driving the need for therapeutic interventions. Therefore, as Cancer and Radiation Therapy Centres continue to expand and cater to the increasing number of cancer patients, they are poised to play a central role in fueling the growth of the Cancer Therapeutics Market.

Could North America Drive an Increase in the Sales within the Cancer Therapeutics Market?

An increase in sales within the Cancer Therapeutics Market could be driven by North America. The region is positioned to dominate the market, primarily due to the widespread adoption of cancer therapeutics and significant funding provided by various organizations operating within the region. With advanced cancer treatment options being widely adopted and substantial financial support being provided by both public and private sectors in North America, the region is poised to stimulate growth in sales within the Cancer Therapeutics Market.

Furthermore, North America's leadership in the adoption of advanced cancer treatment options and its robust financial support from both public and private sectors contribute to its advantageous position. This favorable environment fosters a conducive landscape for the expansion of cancer therapeutics sales, positioning North America as a key driver of market growth.

Will the Sales of Cancer Therapeutics Market fare well in Asia Pacific?

The sales of the Cancer Therapeutics Market are expected to perform well in the Asia Pacific region. With high prevalence of cancer and increasing awareness about the importance of early detection and treatment, there is a significant growth in demand for cancer therapeutics in Asia Pacific. The region's potential for robust sales of cancer therapeutics is further enhanced by advancements in healthcare infrastructure and increasing investments in research and development activities. A surge in collaborations between pharmaceutical companies and healthcare institutions is being witnessed in this region, fostering innovation and the introduction of novel cancer treatment options, driving market growth.

The Government initiatives aimed at improving cancer care and access to treatment, along with the growing adoption of personalized medicine approaches, are expected to bolster the sales of cancer therapeutics in Asia Pacific. As healthcare systems in countries across the Asia Pacific continue to evolve and improve, there is a growing focus on addressing the unmet medical needs of cancer patients, presenting significant opportunities for market expansion in the region.

Competitive Landscape

Examining the competitive landscape of the Cancer Therapeutics Market is considered crucial for gaining insights into the industry's dynamics. This research aims to analyze the competitive landscape, focusing on key players, market trends, innovations, and strategies. By conducting this analysis, valuable insights will be provided to industry stakeholders, assisting them in effectively navigating the competitive environment and seizing emerging opportunities. Understanding the competitive landscape will enable stakeholders to make informed decisions, adapt to market trends, and develop strategies to enhance their market position and competitiveness in the Cancer Therapeutics Market.

Some of the prominent players operating in the Cancer Therapeutics Market include:

Hoffmann-La Roche AG, Bristol-Myers Squibb Company, AbbVie, Inc., Johnson & Johnson, Celgene Corporation, Astellas Pharma Inc., Pfizer Inc., Novartis AG, Merck KGaA, Bayer AG, and Takeda Pharmaceutical Company Limited.

Latest Developments

In February 2024, Bristol-Myers Squibb attained FDA approval for OPDIVO (nivolumab) alongside Yervoy (ipilimumab) for the initial treatment of patients diagnosed with locally advanced or metastatic urothelial carcinoma (bladder cancer).

In February 2024, Merck & Co. revealed encouraging outcomes from a Phase 3 clinical trial of Keytruda (pembrolizumab) combined with chemotherapy as the primary therapy for advanced non-small cell lung cancer (NSCLC). The study exhibited a statistically significant enhancement in overall survival in comparison to chemotherapy alone.

In January 2024, Johnson & Johnson's Janssen unit disclosed favorable findings from a Phase 3 trial of Darzalex (daratumumab) combined with bortezomib and lenalidomide for managing patients with newly diagnosed multiple myeloma. The study highlighted a statistically significant advancement in progression-free survival when contrasted with the administration of lenalidomide and bortezomib alone.

TABLE OF CONTENTS

1. INTRODUCTION OF GLOBAL CANCER THERAPEUTICS MARKET

• 1.1. Overview of the Market
• 1.2. Scope of Report
• 1.3. Assumptions

2. EXECUTIVE SUMMARY

3. RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1. Data Mining
• 3.2. Validation
• 3.3. Primary Interviews
• 3.4. List of Data Sources

4. GLOBAL CANCER THERAPEUTICS MARKET OUTLOOK

• 4.1. Overview
• 4.2. Market Dynamics
  • 4.2.1. Drivers
  • 4.2.2. Restraints
  • 4.2.3. Opportunities
• 4.3. Porters Five Force Model
• 4.4. Value Chain Analysis

5. GLOBAL CANCER THERAPEUTICS MARKET, BY CANCER TYPE

• 5.1. Overview
• 5.2. Blood Cancer
• 5.3. Lung Cancer
• 5.4. Breast Cancer
• 5.5. Gastrointestinal Cancer
• 5.6. Colorectal Cancer
• 5.7. Gynecologic Cancer
• 5.8. Prostate Cancer
• 5.9. Others

6. GLOBAL CANCER THERAPEUTICS MARKET, BY THERAPY

• 6.1. Overview
• 6.2. Chemotherapy
• 6.3. Targeted Therapy
• 6.4. Immunotherapy
• 6.5. Hormonal Therapy
• 6.6. Others

7. GLOBAL CANCER THERAPEUTICS MARKET, BY END USERS

• 7.1. Overview
• 7.2. Hospitals
• 7.3. Specialty Clinics
• 7.4. Cancer and Radiation Therapy Centres

8. GLOBAL CANCER THERAPEUTICS MARKET, BY GEOGRAPHY

• 8.1. Overview
• 8.2. North America
  • 8.2.1. U.S.
  • 8.2.2. Canada
  • 8.2.3. Mexico
• 8.3. Europe
  • 8.3.1. Germany
  • 8.3.2. U.K.
  • 8.3.3. France
  • 8.3.4. Rest of Europe
• 8.4. Asia Pacific
  • 8.4.1. China
  • 8.4.2. Japan
  • 8.4.3. India
  • 8.4.4. Rest of Asia Pacific
• 8.5. Rest of the World
  • 8.5.1. Latin America
  • 8.5.2. Middle East & Africa

9. GLOBAL CANCER THERAPEUTICS MARKET COMPETITIVE LANDSCAPE

• 9.1. Overview
• 9.2. Company Market Ranking
• 9.3. Key Development Strategies

10. COMPANY PROFILES

• 10.1. F. Hoffmann-La Roche AG
  • 10.1.1. Overview
  • 10.1.2. Financial Performance
  • 10.1.3. Product Outlook
  • 10.1.4. Key Developments
• 10.2. Bristol-Myers Squibb Company
  • 10.2.1. Overview
  • 10.2.2. Financial Performance
  • 10.2.3. Product Outlook
  • 10.2.4. Key Developments
• 10.3. AbbVie, Inc.
  • 10.3.1. Overview
  • 10.3.2. Financial Performance
  • 10.3.3. Product Outlook
  • 10.3.4. Key Developments
• 10.4. Johnson & Johnson
  • 10.4.1. Overview
  • 10.4.2. Financial Performance
  • 10.4.3. Product Outlook
  • 10.4.4. Key Developments
• 10.5. Celgene Corporation
  • 10.5.1. Overview
  • 10.5.2. Financial Performance
  • 10.5.3. Product Outlook
  • 10.5.4. Key Developments
• 10.6. Astellas Pharma Inc.
  • 10.6.1. Overview
  • 10.6.2. Financial Performance
  • 10.6.3. Product Outlook
  • 10.6.4. Key Developments
• 10.7. Pfizer, Inc.
  • 10.7.1. Overview
  • 10.7.2. Financial Performance
  • 10.7.3. Product Outlook
  • 10.7.4. Key Developments
• 10.8. Novartis AG
  • 10.8.1. Overview
  • 10.8.2. Financial Performance
  • 10.8.3. Product Outlook
  • 10.8.4. Key Developments
• 10.9. Merck KGaA
  • 10.9.1. Overview
  • 10.9.2. Financial Performance
  • 10.9.3. Product Outlook
  • 10.9.4. Key Developments
• 10.10. Bayer AG
  • 10.10.1. Overview
  • 10.10.2. Financial Performance
  • 10.10.3. Product Outlook
  • 10.10.4. Key Developments

11. Appendix

• 11.1. Related Research